Orphazyme Names Anders Vadsholt CEO as Bourdon Heads to LEO Pharma
February 1, 2022
Rare disease drug developer Orphazyme said it has named its Chief Financial Officer Anders Vadshold to replace its existing CEO Christophe Bourdon, who will resign from his position to take the role as CEO of LEO Pharma April 1, 2022.
Bourdon navigated Orphazyme through turbulent times and has identified a pathway to continue to pursue the approval of the company’s experimental therapy arimoclomol for the treatment of Niemann-Pick disease type C (NPC) in both Europe and the United States, the company said.
“Having held the position of CFO since 2016, Anders brings great understanding of the goals and values at Orphazyme and his appointment as CEO ensures continuity in leadership at the company for the important journey ahead – especially, leading the team during the important next steps for Orphazyme as we work to deliver on our commitment to NPC patients,” said Georges Gemayel, chairman of Orphanzyme.
Author: Rare Daily Staff
Sign up for updates straight to your inbox.